Human-first Biodynamic Discovery PlatformTM employs cutting-edge chemistry, neuroscience,
and machine learning to advance plant- and fungi-inspired therapeutics to address global crisis

Company’s scientific founders include leading experts in neuroscience, chemistry, and psychiatry

Financing led by Santé Ventures, Route 66 Ventures, and CU Healthcare Innovation Fund

BOSTON, Mass., November 8, 2022 – Sensorium Therapeutics (Sensorium), a biotechnology
company leveraging medicinal chemistry, neuroscience, and machine learning to develop
nature-inspired psychoactive medicines for mental health, today announced the closing of a $30
million Series A financing to advance its initial asset, SENS-01, and Biodynamic Discovery
PlatformTM (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances
targeted molecules as novel therapeutics. The round was led by Santé Ventures, a specialized
healthcare and life sciences investment firm with approximately $1 billion in capital under
management, with participation from Route 66 Ventures, CU Healthcare Innovation Fund,
WPSS.bio, Palo Santo, Iter Investments, Ocama Partners, and re.Mind Capital.

“To address this devastating mental health crisis, we urgently need to broaden the universe of
safe and effective treatments by leveraging knowledge about what has worked in human
populations for centuries,” said Dick Simon, Chief Executive Officer and Co-founder of
Sensorium. “The complexity of the challenge requires clinical, scientific, and technical expertise.
Sensorium’s multi-disciplinary team embodies a wealth of industry and academic experience
with a passion and track record for impact.”

With scientific co-founders who are experts in psychiatry, chemistry and neuroscience at leading
institutions, Sensorium seeks to overcome historical challenges in central nervous system drug
development by tapping into the vast chemical space of psychoactive molecules to develop
novel medicines that address the global crisis. Beginning with evidence of efficacy and safety
based on extensive long-term human use, the BDP feeds data outputs from its natural product
library and high-throughput characterization into proprietary machine learning algorithms. By
prioritizing mechanisms with established efficacy in human brains, the platform enables
Sensorium to deliver modern medicines faster and with improved efficacy and tolerability, fewer
side effects, and decreased potential for dependence.

The company’s initial asset SENS-01, shows promise to deliver swift therapeutic effect for
treating anxiety. Sensorium is developing SENS-01 as a rapid-acting and well-tolerated
therapeutic for patients with anxiety and depression and expects to begin IND-enabling studies
in 2023 and enter the clinic by early 2024.

“Sensorium’s transformational technology and experienced research team has the potential to
revolutionize neuropsychiatric therapy by developing multiple new classes of novel
therapeutics,” said Kevin Lalande, Founding Managing Director of Santé Ventures. “We are thrilled to support the Sensorium team on their mission to forge these new treatment pathways
and deliver new medicines to the many patients struggling with urgent mental health needs.”

Sensorium’s Scientific Co-founders added:

• “By better understanding how novel psychoactive molecules impact the brain, we’re
  unlocking critical insights to deliver transformative medicines for patients for whom
  existing treatments fall short and who are desperately awaiting innovation,” said Dr.
  Jerry Rosenbaum, Sensorium Co-founder, Psychiatrist-in-Chief Emeritus and Director
  Emeritus, Center for Anxiety and Traumatic Stress Disorders, at Massachusetts General
  Hospital (MGH); Director, Center for the Neuroscience of Psychedelics; and Stanley
  Cobb Professor of Psychiatry at Harvard Medical School.
• “Our predictive knowledge network of psychoactive molecules identifies structure-activity
  relationships, acting as a springboard for developing novel medicines with optimized
  therapeutic benefit. Nature has provided the template, and we know we can do it better,”
  said Jacob Hooker, Ph.D., Sensorium Co-founder, Scientific Director of the Lurie
  Center for Autism at MGH, Phyllis and Jerome Lyle Rappaport MGH Research Scholar,
  and Professor of Radiology at Harvard Medical School.
• “Humans have consumed psychoactive molecules for centuries, yet how they function
  has remained a challenge to understand. Our approach marries deep knowledge of the
  chemical space with a platform that interrogates drug function on neuronal plasticity and
  other indicators to generate potential drug candidates,” said Stephen Haggarty, Ph.D.,
  Sensorium Co-founder, Associate Professor of Neurology at Harvard Medical School,
  Associate Neuroscientist at MGH, and Director of the MGH Chemical Neurobiology

The financing will support advancement of Sensorium’s platform and initial program and will
also help secure growth of the company’s multi-disciplinary team of experts with a passion for
improving mental health.

About Sensorium Therapeutics
Founded by world-class researchers, clinicians, and drug developers from Massachusetts
General Hospital and Harvard Medical School, Sensorium Therapeutics is biotechnology
company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop
nature-inspired psychoactive medicines for mental health. Beginning with evidence of efficacy
and safety based on extensive long-term human use of plants and fungi, Sensorium’s
groundbreaking Biodynamic Discovery PlatformTM rapidly identifies, reproduces, adapts, and
enhances targeted molecules and elevates their utility as modern medicines that can deliver
transformational benefits to patients around the world. Visit sensorium.bio to learn more.